Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
-
AGTC Announces Proposed Public Offering of Common Stock
-
AGTC Announces Proposed Public Offering of Common Stock
-
AGTC to Participate in Upcoming Investor Conferences
-
AGTC to Participate in Upcoming Investor Conferences
-
AGTC to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
-
Pre-Open Stock Movers 01/28: (KOSS) (HIMS) (EYPT) Higher; (AMC) (BBY) (NOK) (EXPR) Lower (more...)
-
After-Hours Stock Movers 01/27: (EYPT) (AGTC) (NOW) Higher; (AMC) (AXDX) (EXPR) Lower (more...)
-
AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
-
AGTC to Participate at Upcoming Virtual Investor Conferences
-
Pre-Open Stock Movers 06/23: (TBIO) (APYX) (PTN) Higher; (SNSS) (SINT) (LK) Lower (more...)
-
After-Hours Stock Movers 06/22: (APYX) (AGTC) (MYOV) Higher; (ONEM) (TMUS) Lower (more...)
-
Cantor Fitzgerald Starts Applied Genetic Technologies Corp. (AGTC) at Overweight
-
Cantor Fitzgerald Downgrades Applied Genetic Technologies Corp. (AGTC) to Hold
-
AGTC to Present at the Cantor Fitzgerald Second Annual Healthcare Conference on July 13, 2016
-
Cantor Fitzgerald Reiterates Buy on Applied Genetic Technologies (AGTC) Following Recent Positive Gene Therapy News
-
AGTC President & CEO to Present at Cantor Healthcare Conference on July 8, 2015
-
AGTC President & CEO to Present at Cantor Healthcare Conference on July 8, 2015
-
Applied Genetic Technologies (AGTC) PT Raised to $32 at Cantor Fitzgerald on Biogen Deal
-
AGTC Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Applied Genetic Technologies (AGTC) Prices 2M Common Offering at $15/Share
-
AGTC Announces Pricing of Public Offering
-
Notable Analyst Rating Changes 04/21: (MS) (AWI) (HNI) Upgraded; (WLT) (MGI) (YUM) Downgraded
-
UPDATE: Cantor Fitzgerald Starts Applied Genetic Technologies Corp. (AGTC) at Buy
-
AGTC Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Applied Genetic Technologies (AGTC) IPO Opens Higher
-
Applied Genetic Technologies (AGTC) IPO Prices at $12, Below Range
-
AGTC Announces Pricing of Initial Public Offering
-
Applied Genetic Technologies (AGTC) Files $70M IPO

